Revvity Research and Development Expenses 2010-2024 | RVTY
Revvity annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Revvity research and development expenses for the quarter ending December 31, 2024 were $0.049B, a 0.78% decline year-over-year.
- Revvity research and development expenses for the twelve months ending December 31, 2024 were $0.197B, a 9.11% decline year-over-year.
- Revvity annual research and development expenses for 2024 were $0.197B, a 9.11% decline from 2023.
- Revvity annual research and development expenses for 2023 were $0.217B, a 2.27% decline from 2022.
- Revvity annual research and development expenses for 2022 were $0.222B, a 10.62% increase from 2021.
| Revvity Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024 | $197 |
| 2023 | $217 |
| 2022 | $222 |
| 2021 | $200 |
| 2020 | $146 |
| 2019 | $189 |
| 2018 | $194 |
| 2017 | $139 |
| 2016 | $124 |
| 2015 | $113 |
| 2014 | $108 |
| 2013 | $132 |
| 2012 | $132 |
| 2011 | $116 |
| 2010 | $95 |
| 2009 | $90 |
| Revvity Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-12-31 | $49 |
| 2024-09-30 | $49 |
| 2024-06-30 | $48 |
| 2024-03-31 | $50 |
| 2023-12-31 | $50 |
| 2023-09-30 | $53 |
| 2023-06-30 | $57 |
| 2023-03-31 | $57 |
| 2022-12-31 | $55 |
| 2022-09-30 | $54 |
| 2022-06-30 | $56 |
| 2022-03-31 | $58 |
| 2021-12-31 | $25 |
| 2021-09-30 | $49 |
| 2021-06-30 | $66 |
| 2021-03-31 | $60 |
| 2020-12-31 | $-2 |
| 2020-09-30 | $50 |
| 2020-06-30 | $50 |
| 2020-03-31 | $49 |
| 2019-12-31 | $48 |
| 2019-09-30 | $45 |
| 2019-06-30 | $48 |
| 2019-03-31 | $48 |
| 2018-12-31 | $52 |
| 2018-09-30 | $49 |
| 2018-06-30 | $47 |
| 2018-03-31 | $46 |
| 2017-12-31 | $38 |
| 2017-09-30 | $35 |
| 2017-06-30 | $34 |
| 2017-03-31 | $33 |
| 2016-12-31 | $33 |
| 2016-09-30 | $30 |
| 2016-06-30 | $32 |
| 2016-03-31 | $30 |
| 2015-12-31 | $17 |
| 2015-09-30 | $31 |
| 2015-06-30 | $33 |
| 2015-03-31 | $32 |
| 2014-12-31 | $18 |
| 2014-09-30 | $30 |
| 2014-06-30 | $30 |
| 2014-03-31 | $29 |
| 2013-12-31 | $32 |
| 2013-09-30 | $31 |
| 2013-06-30 | $34 |
| 2013-03-31 | $34 |
| 2012-12-31 | $33 |
| 2012-09-30 | $32 |
| 2012-06-30 | $34 |
| 2012-03-31 | $33 |
| 2011-12-31 | $32 |
| 2011-09-30 | $30 |
| 2011-06-30 | $28 |
| 2011-03-31 | $26 |
| 2010-12-31 | $25 |
| 2010-09-30 | $24 |
| 2010-06-30 | $23 |
| 2010-03-31 | $23 |
| 2009-12-31 | $15 |
| 2009-09-30 | $23 |
| 2009-06-30 | $26 |
| 2009-03-31 | $26 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.225B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.654B | 26.76 |
| Elevance Health (ELV) | United States | $95.024B | 12.26 |
| CVS Health (CVS) | United States | $84.108B | 12.31 |
| Cencora (COR) | United States | $56.754B | 20.60 |
| Natera (NTRA) | United States | $20.404B | 0.00 |
| DiDi Global (DIDIY) | China | $19.733B | 29.00 |
| BioMerieux (BMXMF) | France | $15.507B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.474B | 0.00 |
| ICON (ICLR) | Ireland | $12.230B | 11.37 |
| Solventum (SOLV) | United States | $11.439B | 10.66 |
| CochLear (CHEOY) | Australia | $11.362B | 0.00 |
| Doximity (DOCS) | United States | $10.619B | 55.22 |
| Viatris (VTRS) | United States | $10.051B | 3.18 |
| Medpace Holdings (MEDP) | United States | $8.864B | 23.54 |
| Avantor (AVTR) | United States | $8.852B | 12.86 |
| Sonic Healthcare (SKHHY) | Australia | $8.023B | 0.00 |
| HealthEquity (HQY) | United States | $7.414B | 36.48 |
| Charles River Laboratories (CRL) | United States | $5.826B | 11.49 |
| Amplifon S.p.A (AMFPF) | Italy | $4.285B | 22.62 |
| Bausch + Lomb (BLCO) | Canada | $4.085B | 24.08 |
| Alignment Healthcare (ALHC) | United States | $3.503B | 0.00 |
| Organon (OGN) | United States | $3.361B | 3.39 |
| Sotera Health (SHC) | United States | $3.264B | 18.85 |
| BrightSpring Health Services (BTSG) | United States | $3.069B | 31.87 |
| Surgery Partners (SGRY) | United States | $2.814B | 32.28 |
| Concentras Parent (CON) | United States | $2.788B | 14.50 |
| Progyny (PGNY) | United States | $1.957B | 43.09 |
| GeneDx Holdings (WGS) | United States | $1.876B | 73.46 |
| Premier (PINC) | United States | $1.858B | 11.90 |
| Ardent Health Partners (ARDT) | United States | $1.817B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.776B | 38.58 |
| Agilon Health (AGL) | United States | $1.759B | 0.00 |
| PACS (PACS) | United States | $1.468B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.260B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.105B | 9.27 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| CareDx (CDNA) | United States | $0.938B | 14.68 |
| Establishment Labs Holdings (ESTA) | $0.875B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.780B | 6.17 |
| Embecta (EMBC) | United States | $0.709B | 4.86 |
| Nutex Health (NUTX) | United States | $0.608B | 11.91 |
| QDM (QDMI) | Hong Kong, SAR China | $0.583B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.511B | 13.55 |
| Sonida Senior Living (SNDA) | United States | $0.438B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.423B | 0.00 |
| Enhabit (EHAB) | United States | $0.405B | 38.05 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.369B | 0.00 |
| SBC Medicals (SBC) | United States | $0.331B | 0.00 |
| LifeMD (LFMD) | United States | $0.324B | 0.00 |
| DocGo (DCGO) | United States | $0.227B | 9.29 |
| Oncology Institute (TOI) | United States | $0.187B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.185B | 0.00 |
| Beauty Health (SKIN) | United States | $0.124B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.111B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.092B | 0.00 |
| OncoCyte (OCX) | United States | $0.088B | 0.00 |
| So-Young (SY) | China | $0.084B | 0.00 |
| Biodesix (BDSX) | United States | $0.078B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.075B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.070B | 0.00 |
| NeueHealth (NEUE) | United States | $0.057B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.021B | 0.00 |
| ModivCare (MODV) | United States | $0.017B | 5.95 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| KindlyMD (KDLY) | United States | $0.011B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |